Skip to content
2000
Volume 32, Issue 5
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder caused by mutations in the DMD gene, leading to progressive muscle degeneration, loss of ambulation, cardiomyopathy, and early mortality. While advances in multidisciplinary care and pharmacological interventions, including corticosteroids and exon-skipping therapies, have improved patient outcomes, current treatments primarily provide symptomatic relief without addressing the underlying genetic defect. Gene therapy has emerged as a promising approach to modify disease progression, particularly through the use of adeno-associated virus (AAV)-mediated delivery of micro-dystrophin constructs. These truncated genes retain essential functional domains, enabling the restoration of dystrophin expression within the packaging limits of AAV vectors. Early-phase clinical trials have demonstrated encouraging safety profiles and transgene expression; however, challenges such as immune responses, variability in functional improvement, and long-term durability remain. Recent innovations, including optimized AAV capsids, immunomodulatory strategies, and genome editing technologies like CRISPR-Cas9, are actively being explored to overcome these barriers. Additionally, scalable vector manufacturing and the integration of real-world data are essential for broader clinical translation. This review synthesizes current advancements, clinical milestones, and future directions in gene therapy for DMD, emphasizing the need for precise dosing, long-term efficacy, and equitable access to fully realize the therapeutic potential of these evolving strategies.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128386290250507101412
2025-05-12
2026-03-09

  • From This Site

    /content/journals/cpd/10.2174/0113816128386290250507101412
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MahJ.K. KorngutL. DykemanJ. DayL. PringsheimT. JetteN. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy.Neuromuscul. Disord.201424648249110.1016/j.nmd.2014.03.00824780148
     [Google Scholar]
  2. HoffmanE.P. BrownR.H.Jr KunkelL.M. Dystrophin: The protein product of the duchenne muscular dystrophy locus.Cell198751691992810.1016/0092‑8674(87)90579‑43319190
     [Google Scholar]
  3. GaworM. PrószyńskiT.J. The molecular cross talk of the dystrophin–glycoprotein complex.Ann. N. Y. Acad. Sci.201814121627210.1111/nyas.1350029068540
     [Google Scholar]
  4. ErvastiJ.M. CampbellK.P. Membrane organization of the dystrophin-glycoprotein complex.Cell19916661121113110.1016/0092‑8674(91)90035‑W1913804
     [Google Scholar]
  5. BelhasanD.C. AkaabouneM. The role of the dystrophin glycoprotein complex on the neuromuscular system.Neurosci. Lett.202072213483310.1016/j.neulet.2020.13483332057921
     [Google Scholar]
  6. BushbyK. FinkelR. BirnkrantD.J. CaseL.E. ClemensP.R. CripeL. KaulA. KinnettK. McDonaldC. PandyaS. PoyskyJ. ShapiroF. TomezskoJ. ConstantinC. DMD Care Considerations Working Group Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management.Lancet Neurol.201091779310.1016/S1474‑4422(09)70271‑619945913
     [Google Scholar]
  7. BirnkrantD.J. BushbyK. BannC.M. AlmanB.A. ApkonS.D. BlackwellA. CaseL.E. CripeL. HadjiyannakisS. OlsonA.K. SheehanD.W. BolenJ. WeberD.R. WardL.M. DMD Care Considerations Working Group Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management.Lancet Neurol.201817434736110.1016/S1474‑4422(18)30025‑529395990
     [Google Scholar]
  8. CzifrusE. BerlauD.J. Corticosteroids for the treatment of Duchenne muscular dystrophy: A safety review.Expert Opin. Drug Saf.202423101237124710.1080/14740338.2024.239457839152782
     [Google Scholar]
  9. RyderS. LeadleyR.M. ArmstrongN. WestwoodM. de KockS. ButtT. JainM. KleijnenJ. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review.Orphanet J. Rare Dis.20171217910.1186/s13023‑017‑0631‑328446219
     [Google Scholar]
  10. SrivastavaS. AnbiaeeR. HoushyariM. Laxmi SridharS.B. AshiqueS. HussainS. KumarS. TajT. AkbarnejadZ. Taghizadeh-HesaryF. Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance.Cancer Cell Int.20252518910.1186/s12935‑025‑03721‑140082966
     [Google Scholar]
  11. MendellJ.R. Rodino-KlapacL.R. SahenkZ. RoushK. BirdL. LowesL.P. AlfanoL. GomezA.M. LewisS. KotaJ. MalikV. ShontzK. WalkerC.M. FlaniganK.M. CorridoreM. KeanJ.R. AllenH.D. ShillingC. MeliaK.R. SazaniP. SaoudJ.B. KayeE.M. Eteplirsen Study Group Eteplirsen for the treatment of Duchenne muscular dystrophy.Ann. Neurol.201374563764710.1002/ana.2398223907995
     [Google Scholar]
  12. TakedaS. ClemensP.R. HoffmanE.P. Exon-skipping in Duchenne muscular dystrophy.J. Neuromuscul. Dis.20218s2S343S35810.3233/JND‑21068234180420
     [Google Scholar]
  13. PattersonG. ConnerH. GronemanM. BlavoC. ParmarM.S. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach.Eur. J. Pharmacol.202394717567536963652
     [Google Scholar]
  14. AhmetA. TobinR. DangU.J. RoomanR. GuglieriM. ClemensP.R. HoffmanE.P. WardL.M. Adrenal suppression from vamorolone and prednisone in Duchenne muscular dystrophy: Results from the phase 2b clinical trial.J. Clin. Endocrinol. Metab.2025110233434410.1210/clinem/dgae52139097643
     [Google Scholar]
  15. DuanD. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy.Mol Ther.20182870170310.1016/j.ymthe.2018.07.011
     [Google Scholar]
  16. AnthonyK. FengL. Arechavala-GomezaV. GuglieriM. StraubV. BushbyK. CirakS. MorganJ. MuntoniF. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.Hum. Gene Ther. Methods201223533634510.1089/hgtb.2012.11723075107
     [Google Scholar]
  17. MendellJ.R. SahenkZ. LehmanK. NeaseC. LowesL.P. MillerN.F. IammarinoM.A. AlfanoL.N. NichollA. Al-ZaidyS. LewisS. ChurchK. ShellR. CripeL.H. PotterR.A. GriffinD.A. PozsgaiE. DugarA. HoganM. Rodino-KlapacL.R. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy.JAMA Neurol.20207791122113110.1001/jamaneurol.2020.148432539076
     [Google Scholar]
  18. MendellJ.R. ShiehP.B. McDonaldC.M. SahenkZ. LehmanK.J. LowesL.P. ReashN.F. IammarinoM.A. AlfanoL.N. SaboB. WoodsJ.D. SkuraC.L. MaoH.C. StaudtL.A. GriffinD.A. LewisS. WangS. PotterR.A. SinghT. Rodino-KlapacL.R. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy.Front. Cell Dev. Biol.202311116776210.3389/fcell.2023.116776237497476
     [Google Scholar]
  19. LutsykK. GicquelT. CortialL. ForgetS. BraunS. BoyerP.O. LaugelV. BlinO. Does gene therapies clinical research in rare diseases reflects the competitivity of the country: Example of France.Therapie202479550551810.1016/j.therap.2024.01.00738458946
     [Google Scholar]
  20. Rodríguez-MárquezE. MeumannN. BüningH. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.Expert Opin. Biol. Ther.202121674976610.1080/14712598.2021.186530333331201
     [Google Scholar]
  21. ChenG. WeiT. YangH. LiG. LiH. CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: Advances, challenges and perspectives.Cells20221119296410.3390/cells1119296436230926
     [Google Scholar]
  22. NelsonC.E. HakimC.H. OusteroutD.G. ThakoreP.I. MorebE.A. RiveraR.M.C. MadhavanS. PanX. RanF.A. YanW.X. AsokanA. ZhangF. DuanD. GersbachC.A. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.Science2016351627140340710.1126/science.aad514326721684
     [Google Scholar]
  23. ChangM. CaiY. GaoZ. ChenX. LiuB. ZhangC. YuW. CaoQ. ShenY. YaoX. ChenX. SunH. Duchenne muscular dystrophy: Pathogenesis and promising therapies.J. Neurol.202327083733374910.1007/s00415‑023‑11796‑x37258941
     [Google Scholar]
  24. DuanD. Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients.Hum. Gene Ther.201829773373610.1089/hum.2018.01229463117
     [Google Scholar]
  25. WangD. TaiP.W.L. GaoG. Adeno-associated virus vector as a platform for gene therapy delivery.Nat. Rev. Drug Discov.201918535837810.1038/s41573‑019‑0012‑930710128
     [Google Scholar]
  26. FatimaR. KhanY. MaqboolM. RamalingamP.S. KhanM.G. BishtA.S. HussainM.S. Amyloid-β clearance with monoclonal antibodies: Transforming Alzheimer’s treatment.Curr. Protein Pept. Sci.202510.2174/011389203736203725020514391139980294
     [Google Scholar]
  27. CalcedoR. VandenbergheL.H. GaoG. LinJ. WilsonJ.M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.J. Infect. Dis.2009199338139010.1086/59583019133809
     [Google Scholar]
  28. ArrudaV.R. XiaoW. It’s all about the clothing: Capsid domination in the adeno-associated viral vector world.J. Thromb. Haemost.200751121510.1111/j.1538‑7836.2006.02262.x17239162
     [Google Scholar]
  29. ColellaP. RonzittiG. MingozziF. Emerging issues in AAV-mediated in vivo gene therapy.Mol. Ther. Methods Clin. Dev.201888710410.1016/j.omtm.2017.11.00729326962
     [Google Scholar]
  30. ChamberlainJR ChamberlainJS Progress toward gene therapy for Duchenne muscular dystrophy.Mol Ther.2017255112510.1016/j.ymthe.2017.02.019
     [Google Scholar]
  31. WangZ. TapscottS.J. ChamberlainJ.S. StorbR. Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials.Front. Microbiol.2011220121980317
     [Google Scholar]
  32. HussainM.S. GuptaG. SamuelV.P. AlmalkiW.H. KazmiI. AlzareaS.I. SaleemS. KhanR. AltwaijryN. PatelS. PatelA. SinghS.K. DuaK. Immunopathology of herpes simplex virus-associated neuroinflammation: Unveiling the mysteries.Rev. Med. Virol.2024341e249137985599
     [Google Scholar]
  33. KornegayJN LiJ BoganJR BoganDJ ChenC ZhengH Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs.Mol Ther.2010188150110.1038/mt.2010.94
     [Google Scholar]
  34. HindererC. KatzN. BuzaE.L. DyerC. GoodeT. BellP. RichmanL.K. WilsonJ.M. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN.Hum. Gene Ther.201829328529829378426
     [Google Scholar]
  35. MingozziF. HighK.A. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy.Blood20131221233623596044
     [Google Scholar]
  36. MuellerC. ChulayJ.D. TrapnellB.C. HumphriesM. CareyB. SandhausR.A. McElvaneyN.G. MessinaL. TangQ. RouhaniF.N. Campbell-ThompsonM. FuA.D. YachnisA. KnopD.R. YeG.J. BrantlyM. CalcedoR. SomanathanS. RichmanL.P. VonderheideR.H. HulmeM.A. BruskoT.M. WilsonJ.M. FlotteT.R. Human treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.J. Clin. Invest.2013123125310531824231351
     [Google Scholar]
  37. BuchlisG. PodsakoffG.M. RaduA. HawkS.M. FlakeA.W. MingozziF. HighK.A. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.Blood2012119133038304110.1182/blood‑2011‑09‑38231722271447
     [Google Scholar]
  38. RogersG.L. MartinoA.T. AslanidiG.V. JayandharanG.R. SrivastavaA. HerzogR.W. Innate immune responses to AAV vectors.Front. Microbiol.2011219421954398
     [Google Scholar]
  39. UematsuS. AkiraS. Toll-like receptors and Type I interferons.J. Biol. Chem.200728221153191532317395581
     [Google Scholar]
  40. WrightJF Codon modification and PAMPs in clinical AAV vectors: The tortoise or the hare?Mol Ther.202028370110.1016/j.ymthe.2020.01.026
     [Google Scholar]
  41. MartinoA.T. SuzukiM. MarkusicD.M. ZolotukhinI. RyalsR.C. MoghimiB. ErtlH.C. MuruveD.A. LeeB. HerzogR.W. The genome of self- complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.Blood2011117246459646821474674
     [Google Scholar]
  42. FaustS.M. BellP. CutlerB.J. AshleyS.N. ZhuY. RabinowitzJ.E. WilsonJ.M. CpG-depleted adeno-associated virus vectors evade immune detection.J. Clin. Invest.201312372994300123778142
     [Google Scholar]
  43. MatthewsE. BrassingtonR. KuntzerT. JichiF. ManzurA.Y. Corticosteroids for the treatment of Duchenne muscular dystrophy.Cochrane Libr.201620166CD00372510.1002/14651858.CD003725.pub427149418
     [Google Scholar]
  44. RosenbergA.S. PuigM. NagarajuK. HoffmanE.P. VillaltaS.A. RaoV.A. WakefieldL.M. WoodcockJ. Immune-mediated pathology in Duchenne muscular dystrophy.Sci. Transl. Med.20157299299rv410.1126/scitranslmed.aaa732226246170
     [Google Scholar]
  45. MackDL PoulardK GoddardMA LatournerieV SnyderJM GrangeRW Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs.Mol Ther20172583985410.1016/j.ymthe.2017.02.004
     [Google Scholar]
  46. JensenT.L. GøtzscheC.R. WoldbyeD.P.D. Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord.Front. Mol. Neurosci.20211469593710.3389/fnmol.2021.69593734690692
     [Google Scholar]
  47. HordeauxJ WangQ KatzN BuzaEL BellP WilsonJM The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice.Mol Ther201826366410.1016/j.ymthe.2018.01.018
     [Google Scholar]
  48. BoisgeraultF. MingozziF. The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer.Curr. Gene Ther.201515438139410.2174/156652321566615063012175026122097
     [Google Scholar]
  49. Le GuinerC. ServaisL. MontusM. LarcherT. FraysseB. MoullecS. AllaisM. FrançoisV. DutilleulM. MalerbaA. KooT. ThibautJ.L. MatotB. DevauxM. Le DuffJ. DeschampsJ.Y. BarthelemyI. BlotS. TestaultI. WahbiK. EderhyS. MartinS. VeronP. GeorgerC. AthanasopoulosT. MasurierC. MingozziF. CarlierP. GjataB. HogrelJ.Y. AdjaliO. MavilioF. VoitT. MoullierP. DicksonG. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.Nat. Commun.201781610528742067
     [Google Scholar]
  50. ChandlerR.J. LaFaveM.C. VarshneyG.K. TrivediN.S. Carrillo-CarrascoN. SenacJ.S. WuW. HoffmannV. ElkahlounA.G. BurgessS.M. VendittiC.P. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy.J. Clin. Invest.2015125287088010.1172/JCI7921325607839
     [Google Scholar]
  51. RussellD.W. GrompeM. Adeno-associated virus finds its disease.Nat. Genet.201547101104110526417859
     [Google Scholar]
  52. NathwaniA.C. ReissU.M. TuddenhamE.G.D. RosalesC. ChowdaryP. McIntoshJ. Della PerutaM. LheriteauE. PatelN. RajD. RiddellA. PieJ. RangarajanS. BevanD. RechtM. ShenY.M. HalkaK.G. Basner-TschakarjanE. MingozziF. HighK.A. AllayJ. KayM.A. NgC.Y.C. ZhouJ. CancioM. MortonC.L. GrayJ.T. SrivastavaD. NienhuisA.W. DavidoffA.M. Long-term safety and efficacy of factor IX gene therapy in hemophilia B.N. Engl. J. Med.2014371211994200410.1056/NEJMoa140730925409372
     [Google Scholar]
  53. Gil-FarinaI FronzaR KaeppelC Lopez-FrancoE FerreiraV D'AvolaD Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients.Mol Ther.201624161100110510.1038/mt.2016.52
     [Google Scholar]
  54. KeelerA.M. FlotteT.R. Recombinant adeno-associated virus gene therapy in light of luxturna (and Zolgensma and Glybera): Where are we, and how did we get here?Annu. Rev. Virol.20196160162110.1146/annurev‑virology‑092818‑01553031283441
     [Google Scholar]
  55. ShenW. LiuS. OuL. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis.Front. Immunol.202213100126336389770
     [Google Scholar]
  56. YoussefE. FletcherB. PalmerD. Enhancing precision in cancer treatment: The role of gene therapy and immune modulation in oncology.Front. Med. (Lausanne)202511152760010.3389/fmed.2024.152760039871848
     [Google Scholar]
  57. Sandoval-VillegasN. NurievaW. AmbergerM. IvicsZ. Contemporary transposon tools: A review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering.Int. J. Mol. Sci.20212210508410.3390/ijms2210508434064900
     [Google Scholar]
  58. HansonB. WoodM.J.A. RobertsT.C. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.RNA Biol.20211871048106210.1080/15476286.2021.187416133472516
     [Google Scholar]
  59. FatehiS. MarksR.M. RokM.J. PerillatL. IvakineE.A. CohnR.D. Advances in CRISPR/Cas9 genome editing for the treatment of muscular dystrophies.Hum. Gene Ther.2023349-1038840310.1089/hum.2023.05937119122
     [Google Scholar]
  60. Martínez-MolinaE. Chocarro-WronaC. Martínez-MorenoD. MarchalJ.A. BoulaizH. Large-scale production of lentiviral vectors: Current perspectives and challenges.Pharmaceutics20201211105110.3390/pharmaceutics1211105133153183
     [Google Scholar]
  61. TripathiN.K. ShrivastavaA. Recent developments in bioprocessing of recombinant proteins: Expression hosts and process development.Front. Bioeng. Biotechnol.2019742010.3389/fbioe.2019.0042031921823
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128386290250507101412
Loading
Expanding the Potential of Gene Therapy for Duchenne Muscular Dystrophy
Curr. Pharm. Des. 32, 330 (2026); https://doi.org/10.2174/0113816128386290250507101412
/content/journals/cpd/10.2174/0113816128386290250507101412
/content/journals/cpd/10.2174/0113816128386290250507101412
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): AAV Vectors; clinical trials; CRISPR-Cas9; dystrophin; gene editing; micro-dystrophin; transgene expression

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test